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1. Introduction 
Signal transduction systems regulate complex biological events such as cell proliferation and 
differentiation via phosphorylation/dephosphorylation kinetic reactions. Therefore, 
dysregulation of these systems lead to a variety of diseases such as diabetes, abnormal bone 
metabolism, autoimmune disease and cancer [1-4]. Above all, cancer is well-known to be 
caused by aberrant regulation of signaling pathways. Although a large number of studies 
regarding phosphorylation events in cancer cell networks were performed, a global view of 
these complex systems has not been fully elucidated.  Recent technological advances in mass 
spectrometry-based proteomics have enabled us to identify thousands of proteins in a single 
project [5-7] and, in combination with relative quantitation techniques such as Stable Isotope 
Labeling by Amino acids in Cell culture (SILAC), quantitative analysis regarding signaling-
related molecules can also be performed [8,9]. Recently, establishment of phosphorylation-
directed peptide/protein enrichment technology has led us to capture the comprehensive 
status of phosphorylated cellular signaling molecules in a time-resolved manner [10-12]. 
Tyrosine-phosphoproteome analysis conducted by utilizing anti-phosphotyrosine 
antibodies unveils key regulatory signaling dynamics triggered by tyrosine kinases such as 
epidermal growth factor receptor (EGFR) in various contexts of cancer cell signaling. 
Furthermore, chemistry-based phosphopeptide enrichment technologies such as 
immobilized metal affinity chromatography (IMAC) [13,14] and metal oxide 
chromatography (MOC) including titanium dioxide (TiO2) allows us to describe a 
serine/threonine/tyrosine-phosphorylation dependent global landscape of cellular signaling 
at the network level [15,16]. In this chapter, we introduce recent technological development 
regarding quantitative phosphoproteomics and discuss the future direction of cancer 
research toward exploration of drug targets in complex signaling networks from a system-
level point of view. 
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2. Shotgun proteomics technology  
2.1. Mass spectrometry-based proteomics methodology 
Recent progress in mass spectrometry-based proteomics technique has greatly contributed 
to elucidation of the regulatory networks constituted by a small amount of signaling-related 
molecules [17]. Especially, modern mass spectrometers termed linear ion trap (LTQ)  
Orbitrap instrument coupled to nano-flow liquid chromatography (nanoLC) enables us to 
identify and quantify thousands of signaling factors, leading to characterize diverse aspects 
of biological processes [18,19]. This system is made up of LTQ [20] and Orbitrap [21], which 
permits reliable peptide identification with high sensitivity, high mass resolution and high 
mass accuracy. In principle, there are two methodologies (in-gel digestion and in-solution 
digestion) for mass spectrometric sample preparation (Figure 1). Recently, liquid-
fractionation entrapment technology has also been developed to improve 
comprehensiveness as well as sensitivity.  
 
Figure 1. Experimental workflow for advanced mass spectrometry-based proteomics. Two standard 
methodologies (in-gel digestion and in-solution digestion) are usually applied to sample preparation. 
2.2. In-solution fractionation techniques  
In order to achieve peptide identification more comprehensively, in-solution fractionation 
techniques including two dimensional (2D) nanoLC system, Gelfree 8100 Fractionation 
System (Protein Discovery) [22] and 3100 OFFGEL Fractionator (Agilent) [23] have been 
developed for further sample separation. 2D nanoLC system consists of on-line strong 
cation exchange (SCX) and reversed-phase (RP) columns (Figure 2A), whereas off-line 
fractionation systems such as Gelfree 8100 Fractionation System and 3100 OFFGEL 
Fractionator separate proteins by molecular weight and isoelectric point, respectively 
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(Figure 2B, 2C). These systems enable us not only to reduce the complexity of samples but 
also to minimize the amount of starting materials compared with in-gel digestion. 
 
 
Figure 2. Schematic illustrations for in-solution protein/peptide separation techniques based on 
fractionation A) using SCX and RP columns (2D nanoLC system), B) by molecular weight (Gelfree 8100 
Fractionation System) and C) by isoelectric point (3100 OFFGEL Fractionator). 
3. Quantitative proteomics  
Quantitative description based on mass spectrometry is not readily available because of the 
principle that ionization efficiency for mass spectrometric detection depends on the 
chemical property of each peptide. In recent years, several methods have been intensively 
developed for absolute and relative quantification [24]. The former methodology enables us 
to determine the absolute amount of proteins using standard peptides or proteins that are 
labeled by stable isotopes [25-27]. Meanwhile, the latter can provide information on the 
relative change in protein/peptide amount. There are two major approaches for relative 
quantification termed label-free and stable isotope-based methods.  
3.1. Label-free methods 
The label-free methods that utilize spectral counting or signal intensity for relative 
quantitation (Figure 3) are simple and economical but less accurate than isotope-based 
methods [28,29]. 
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Figure 3. Representative chromatograms acquired under two different conditions. Relative quantitation 
can be performed by comparing these chromatograms. The red rectangle indicates the peak intensities 
increased in condition 2 compared with condition 1. 
3.2. Stable isotope-based methods 
Stable isotope-based methods allow us to distinguish the status of protein/peptide amount 
of even post translational modifications (PTMs) in a more accurate manner. Stable isotope-
labeled reagents were incorporated into specific amino acids by chemical derivatization or 
metabolic labeling. Isotope-Coded Affinity Tag (ICAT) [30,31], isobaric Tag for Relative and 
Absolute Quantitation (iTRAQ) [32-34] and Tandem Mass Tag (TMT) [35,36] belong to the 
former chemical derivatization techniques. As for metabolic labeling strategies, Stable 
Isotope Labeling by Amino acids in Cell culture (SILAC) technique [37,38] is known as the 
most useful and accurate for relative quantitation.  
3.2.1. ICAT 
The chemical structure of the ICAT reagent consists of three regions: a reactive group with 
cysteine, an isotopically coded linker and a biotin tag (Figure 4). In order to perform a 
quantitative analysis, the cellular proteomes in two different conditions are labeled with 
light and heavy ICAT reagents, respectively. After the two samples are combined, they are 
proteolytically digested and purified with avidin affinity chromatography. The differential 
analyses are sequentially performed by detecting mass shift using liquid chromatography 
combined with tandem mass spectrometry (LC-MS/MS).  
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Figure 4. Peptide quantitation using cleavable ICAT. Differentially labeled peptides with ICAT tag at 
cysteine residues are preferentially enriched and analysed by LC-MS/MS. The ratio of heavy (red peak) 
to light (green peak) area indicates relative abundance of each peptide. 
3.2.2. Isobaric reagents (iTRAQ and TMT) 
The isobaric reagents such as iTRAQ and TMT contain an isobaric tag and an amine specific 
peptide reactive group. This strategy enables us to label all peptides derived from samples. 
Relative quantification of the mixed sample is performed at the MS/MS fragmentation stage 
(Figure 5).  
 
Figure 5. Peptide quantitation using iTRAQ. Peptides labeled by isobaric tags on the N-termini and 
lysine side chains are mixed and analyzed by LC-MS/MS. After fragmentation, MS/MS spectra of 
reporter ions are observed in the low mass region. The ratio of these peaks represents a relative amount 
of each peptide. 
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3.2.3. SILAC 
As for metabolic labeling, Stable Isotope Labeling by Amino acids in Cell culture (SILAC) 
technique has widely been used to quantify protein abundance or PTM status in different 
conditions (Figure 6). Two cell populations are grown in different culture media including 
light or heavy stable isotopes of arginine and/or lysine. The lysates from these cell 
populations are equally combined, proteolytically digested and analyzed by LC-MS/MS. 
Regarding each mass pair detected, the ratio of the peak intensities corresponds to the 
relative peptide abundance.   
 
Figure 6. Peptide quantitation using SILAC. Proteins metabolically labeled by differential stable 
isotopes are combined, proteolytically digested and subjected to nanoLC-MS/MS analysis. The ratio of 
heavy to light peak area accounts for a relative amount of each peptide. 
4. Analytical methodologies for enrichment of phosphorylated molecules 
The mechanistic principles for transmitting signals within cellular networks rely greatly on 
PTMs such as phosphorylation, ubiquitination and acetylation. Although reversible 
phosphorylation events are well-studied in signal transduction research, a global landscape 
of phosphorylation-dependent signaling networks remains almost unclear. Here we 
introduce several phosphoprotein/phosphopeptide enrichment methods for mass 
spectrometry-based global phosphoproteome analysis. 
4.1. Immunoprecipitation using anti-phosphotyrosine antibodies 
Anti-phosphotyrosine antibodies are frequently used to enrich tyrosine-phosphorylated 
proteins (Figure 7A) for analyzing phosphotyrosine-based biological networks using mass 
spectrometry. These are some previous studies in which this methodology was successfully 
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applied for phosphotyrosine-related signaling networks in leukemia cells [39] and human 
HeLa cells [10]. Salomon et al. identified 64 phosphorylation sites on 32 distinct proteins in 
leukemia cells by treatment with STI571 (Gleevec) [39]. Blagoev et al. showed that 81 
signaling related molecules including 31 novel effectors were activated in response to 
epidermal growth factor (EGF) stimulation in a time-dependent manner [10]. These 
researches provided the key aspects of cellular regulation in each signaling context.          
 
Figure 7. Overview of the affinity status of phosphorylated molecules with A) anti-phosphotyrosine 
antibody, B) IMAC, C) Phos-Tag and D) TiO2 
4.2. IMAC 
Immobilized Metal Affinity Chromatography (IMAC) is based on the notion that phosphate 
groups can chelate with metal ions such as iron, zinc or gallium (Figure 7B). Stensballe et al. 
showed that some phosphopeptides could be unambiguously identified using only low-
picomole of samples by Fe(III)-IMAC technique [13]. This approach is also known to be 
suitable for identification of multiply phosphorylated peptides rather than singly modified 
ones. 
4.3. Phos-Tag 
Phos-Tag has a vacancy on two metal ions that is accessible for phosphomonoester dianion 
(Figure 7C). The peptides with phosphorylated serine, threonine and tyrosine residues can 
be all captured by the chemical structure [40,41].  
4.4. TiO2  
Titanium dioxide (TiO2)-based method is one of the most frequently used technique for 
phosphopeptide enrichment (Figure 7D) [15,16].  Olsen et al. detected 6,600 phosphorylation 
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sites on 2,244 proteins in human HeLa cells and showed that 14 % of the identified 
phosphorylation sites were altered by at least 2-fold in response to EGF stimulation [16]. The 
unbiased large-scale phosphoproteome data provided more extensive insights regarding 
phosphorylation-dependent cellular processes.   
5. Proteomics-driven computational analysis  
In recent years, several functional annotation and network analysis tools have been 
developed to understand cellular processes from a system-level point of view. Here we 
introduce two representative computational tools for analyzing large-scale proteome data. 
Database for Annotation, Visualization and Integrated Discovery (DAVID) [42] 
(http://david.abcc.ncifcrf.gov/home.jsp), which consists of an integrated biological 
knowledgebase and some analytical tools, enables extraction of the related information from 
the functional annotation databases (Figure 8). 
 
 
Figure 8. DAVID-based functional description of DNA replication (KEGG pathway). Red symbols 
indicate the molecules detected by the shotgun proteome analysis of glioblastoma stem cells [43]. 
Ingenuity Pathways Analysis (IPA) software (http://www.ingenuity.com) (Ingenuity 
Systems) is used to find networks in relation to experimental proteome data using the 
Ingenuity Knowledge Base derived from thousands of peer-reviewed journals (Figure 9). 
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Figure 9. Representative description using IPA software. A) Statistical classification of canonical 
pathways extracted from experimental data. B) Pathway analysis based on quantitative proteome data.  
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6. Proteomics-based description of cancer signaling networks   
6.1. Phosphoproteome dynamics in cancer cells 
Signal transduction systems regulated by tyrosine phosphorylation events are widely 
known to play a crucial role in fundamental biological processes such as cell proliferation, 
differentiation and migration. Thus, phosphoproteomics-based approaches have first been 
applied to reveal the molecular mechanisms governed by tyrosine phosphorylation in 
response to external growth factors such as EGF [10,11,44,45], fibroblast growth factor (FGF) 
[46] or heregulin (HRG) [47]. Schulze et al. identified interaction partners of the four 
members belonging to the ErbB receptor family (EGFR, ErbB2, ErbB3 and ErbB4) using the 
corresponding synthetic peptides as baits in an unbiased proteomic manner [45]. They 
revealed that most interaction partners to tyrosine residues were located at the C-terminal 
end outside the kinase domain of each ErbB family member. Hinsby et al. demonstrated that 
28 components were induced by basic fibroblast growth factor (bFGF) stimulation in FGFR-1 
expressing cells [46]. The effect of EGF stimulation on human epithelial carcinoma A431 
cells was also examined in a time-resolved manner [11] (Figure 10A). Among a total of 136 
proteins identified, 56 molecules were quantified by more than 1.5-fold changes upon EGF 
stimulation.  Moreover, the temporal perturbation effects of the Src-family kinase inhibitor, 
PP2, on the prolonged activation phase were also evaluated regarding various cellular 
proteins including Src-family kinase substrates. Consequently, the effect of PP2 on the 
molecules which belong to cell adhesion such as Catenin δ showed significant down-
regulation, whereas the impact on the factors related to classical cascades such as EGFR was 
modest (Figure 10B). IPA analysis was then performed to elucidate the PP2 effects on the 
EGF-induced A431 cells at the network level (Figure 11). These results clearly showed the 
differences in tyrosine-phosphorylation levels in the presence or absence of PP2. Thus, these 
data provide further insight into how such complex biological systems would function in 
response to external perturbation. 
By combining quantitative phosphoproteome and transcriptome data in silico, Oyama et al. 
performed a system-level analysis regarding cellular information networks in wild-type 
(WT) and tamoxifen-resistant (TamR) human breast adenocarcinoma MCF-7 cells in 
response to HRG and 17β-estradiol (E2) stimulation [47] (Figure 12). The integrative analysis of 
phosphoproteome and transcriptome in MCF-7 cells revealed that activation of glycogen-
synthase kinase 3β (GSK3β) and mitogen-activated protein kinase (MAPK) 1/3 signaling might 
be associated with altered activation of CREB and AP-1 transcription factors in TamR MCF-7 
cells, which potentially defines drug-resistance properties against tamoxifen (Figure 13).  
6.2. Large-scale proteomic characterization of cancer stem/initiating cells 
Cancer cells are widely known to be heterogeneous, even though they were derived from a 
single transformed cell [48]. Some of them show resistance to anti-cancer drugs and 
radiation therapies [49,50] and recent studies also demonstrated the existence of cancer stem 
cells (CSCs) in various types of cancer cells including leukemia [51], breast cancer [52], 
glioma [53,54] and colon cancer [55,56]. Moreover, it has been getting clear that CSCs have  
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Figure 10. Schematic procedures for identification and SILAC-based quantitation of tyrosine-
phosphoproteome in A431 cells [11]. A) The experimental procedure using three different SILAC media 
to describe tyrosine-phosphoproteome dynamics in response to EGF stimulation. B) Comparative 
analysis using two distinct SILAC media for evaluation of the perturbation effects by Src-family kinase 
inhibitor, PP2.  Green lines show EGF activation profiles ,whereas red ones indicate temporal 
perturbation effects by PP2.       
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Figure 11. Network analysis of the quantitative phosphoproteome data on A431 cells A) upon EGF 
stimulation and B) subsequently perturbed by PP2, respectively. Red and green nodes indicate up- and 
down-regulated signalling molecules, respectively. 
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Figure 12. A schematic procedure for identification and quantitation of large-scale phosphoproteome in 
ligand-stimulated MCF7 cells [47]. The phosphorylated molecules captured by anti-pTyr antibodies or 
Phos-tag agarose were analysed by nanoLC-MS/MS. 
the ability of treatment refractory [57-60] as well as biological properties similar to normal 
stem cells such as self-renewal and differentiation potency [61]. Recent studies also pointed 
out the possibility that CSCs were derived from normal stem cells and any non-CSCs might 
also convert to CSCs [62]. Therefore, comprehensive elucidation of signaling networks in 
CSCs is considered to be one of the most important steps in cancer research. Thus, we 
applied mass spectrometry-based shotgun proteomics technology to characterize protein 
expression profiles [43] and global phosphorylation-dependent signaling networks [63] in 
glioblastoma stem/initiating cells derived from brain tissues (Figure 14). 
In order to gain a comprehensive overview of protein expression in glioblastoma 
stem/initiating cells, we conducted a shotgun proteome analysis, leading to identification of 
2,089 proteins in total [43]. The DAVID-based pathway analysis showed the expressed 
proteome were enriched in ribosome (Figure 15), spliceosome and proteasome to a high 
degree. Thus, global protein expression analysis using advanced mass spectrometry offers 
novel viewpoints for characterization of key factors besides other methodologies such as 
fluorescence-activated cell sorting (FACS) and gene expression analyses.    
The global phosphoproteome analysis of these glioblastoma stem cells also enabled us to 
determine 6,073 phosphopeptides derived from 2,282 proteins using two fragmentation 
methodologies of collision induced dissociation and higher energy C-trap dissociation [63]. 
The IPA analysis of the phosphoproteome data unveiled a variety of canonical pathways 
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that have been reported to play a crucial role in cancer cells and normal stem cells (Figure 
16). Among them, mTOR signaling, which is known to play an important part in stem cell 
regulation [64,65], was found to be one of the most highly enriched pathways. Very 
interestingly, the phosphorylation status of EIF4EBP1 and RPS6, which enhance mRNA 
translation, were up-regulated by EGF stimulation (Figure 17). The analysis also led to 
identification of various novel phosphorylation sites on the molecules with stem cell-like 
and glioma properties such as nestin and vimentin [66]. More intriguingly, some novel 
phosphopeptides derived from undefined regions within the human transcript sequences 
were also determined from the large-scale phosphoproteome data and the phosphorylation 
status of the peptide encoded by supervillin-like (LOC645954) was found to be altered upon 
EGF stimulation (Figure 18). 
 
 
 
 
 
 
 
Figure 13. Integrative network analyses of quantitative phosphoproteome and transcriptome data 
obtained from MCF7 cells A) after HRG stimulation and B) after E2 stimulation. Red and green nodes 
indicate up- and down-regulated signaling molecules, respectively. 
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Figure 14. Schematic procedures for identification and quantitation of the expressed proteome and 
phosphoproteome in glioblastoma stem cells. The whole proteome and phosphoproteome were 
analysed by nanoLC-MS/MS. 
 
Figure 15. DAVID-based functional description of Ribosome pathway (KEGG pathway). Red symbols 
indicate the molecules detected in the proteomic analysis of glioblastoma stem cells [43]. 
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Figure 16. Representative canonical pathways enriched in the phophoproteome of glioblastoma stem 
cells. Red and green bars indicate up- and down-regulation of phosphorylation levels in response to 
EGF stimulation, respectively. Orange dots denote –log(p-value) by Fisher’s Exact test, indicating the 
statistical significance of the molecules in each criterion. 
  
Figure 17. IPA-based network description of mTOR signaling extracted from the large-scale 
phosphoproteome data on glioblastoma stem cells. Red and green nodes indicate up- and down-
regulated signaling effectors in response to EGF stimulation, respectively.     
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Figure 18. Mass spectra of the novel phosphopeptide encoded by supervillin-like (LOC645954) in 
HeLa-derived cells and glioblastoma stem cells upon EGF stimulation [63]. 
7. Conclusion 
Advanced mass spectrometry-based proteomics has become a powerful tool for 
comprehensive understanding of signal transduction networks at the system level. In this 
chapter, we introduced recent proteomics technologies regarding relative quantitation and 
enrichment of phosphorylated proteins/peptides for large-scale description of signaling 
network dynamics. Utilizing these approaches, thousands of phosphorylation sites on 
diverse signaling-related molecules can now be identified in an unbiased fashion. 
Quantitative information on the effects of ligand stimulation and inhibitor perturbation also 
proved beneficial to understand the phosphorylation dynamics at the network level. 
Furthermore, extensive in silico analyses based on comprehensive proteome data enabled us 
to describe a system-level view of biological networks in a statistical manner. Consequently, 
mass-spectrometry-based proteomics will pave the way to evaluate molecular hubs in 
signaling systems and to develop novel targets for treatment of various diseases caused by 
signaling aberration [67,68].   
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